The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 24, 2015

Filed:

Aug. 06, 2012
Applicants:

Qizhi Yao, Houston, TX (US);

Christian Marin-muller, Houston, TX (US);

Changyi Chen, Houston, TX (US);

Inventors:

Qizhi Yao, Houston, TX (US);

Christian Marin-Muller, Houston, TX (US);

Changyi Chen, Houston, TX (US);

Assignee:

Baylor College of Medicine, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C07H 21/02 (2006.01); A01N 63/00 (2006.01); C12Q 1/68 (2006.01); G01N 33/53 (2006.01); A61K 31/7088 (2006.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01); A61K 51/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); A61K 51/00 (2013.01); A61K 2300/00 (2013.01); Y10T 428/13 (2015.01); Y10S 977/704 (2013.01);
Abstract

A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual.


Find Patent Forward Citations

Loading…